Guidelines on the management of Waldenström macroglobulinaemia
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2006-03, Vol.132 (6), p.683-697 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 697 |
|---|---|
| container_issue | 6 |
| container_start_page | 683 |
| container_title | British journal of haematology |
| container_volume | 132 |
| creator | Johnson, S. A. Birchall, J. Luckie, C. Oscier, D. G. Owen, R. G. |
| description | |
| doi_str_mv | 10.1111/j.1365-2141.2005.05948.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67671277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67671277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3978-775eb591201a6ba172bbce04819d16e3d786e64206969d2f5d60cce9980736643</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EoqXwCygb2CXM5GHHC4SgghZUiQ2IpeUkk5IqjxInov0xfoAfI6ER3eKNLc25nqvDmIXgYHeuVg56PLBd9NFxAQIHAumHzuaAjf8Gh2wMAMJG8MMROzFmBYAeBHjMRsj9UCCXY3Yza7OE8qwkY1Wl1byTVehSL6mgsrGq1HrTeUKlaervr6IbxXW1zKuo7RKaikyfsqNU54bOhnvCXh_uX6Zze_E8e5zeLuzYkyK0hQgoCiS6gJpHGoUbRTF1zVAmyMlLRMiJ-y5wyWXipkHCIY5JyhCEx7nvTdjl7t91XX20ZBpVZCamPNclVa1RXHCBrhAdGO7ArqkxNaVqXWeFrrcKQfXy1Er1jlTvSPXy1K88temi58OONioo2QcHWx1wMQDaxDpPa13GmdlzIvBC4H2H6x33meW0_XcBdfc071_eD6vLieo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67671277</pqid></control><display><type>article</type><title>Guidelines on the management of Waldenström macroglobulinaemia</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Johnson, S. A. ; Birchall, J. ; Luckie, C. ; Oscier, D. G. ; Owen, R. G.</creator><creatorcontrib>Johnson, S. A. ; Birchall, J. ; Luckie, C. ; Oscier, D. G. ; Owen, R. G. ; Haemato-Oncology Task Force of the British Committee for Standards in Haematology</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2005.05948.x</identifier><identifier>PMID: 16487169</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Biological and medical sciences ; Cladribine - therapeutic use ; diagnosis ; Drug Therapy, Combination ; Enzyme Inhibitors - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunologic Factors - therapeutic use ; Immunopathology ; Immunosuppressive Agents - therapeutic use ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Plasma Exchange ; Prognosis ; Rituximab ; Stem Cell Transplantation - methods ; Thalidomide - therapeutic use ; treatment ; Vidarabine - analogs & derivatives ; Vidarabine - therapeutic use ; Waldenstrom Macroglobulinemia - drug therapy ; Waldenstrom Macroglobulinemia - immunology ; Waldenstrom Macroglobulinemia - therapy ; Waldenström macroglobulinaemia</subject><ispartof>British journal of haematology, 2006-03, Vol.132 (6), p.683-697</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3978-775eb591201a6ba172bbce04819d16e3d786e64206969d2f5d60cce9980736643</citedby><cites>FETCH-LOGICAL-c3978-775eb591201a6ba172bbce04819d16e3d786e64206969d2f5d60cce9980736643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2005.05948.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2005.05948.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17538067$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16487169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, S. A.</creatorcontrib><creatorcontrib>Birchall, J.</creatorcontrib><creatorcontrib>Luckie, C.</creatorcontrib><creatorcontrib>Oscier, D. G.</creatorcontrib><creatorcontrib>Owen, R. G.</creatorcontrib><creatorcontrib>Haemato-Oncology Task Force of the British Committee for Standards in Haematology</creatorcontrib><title>Guidelines on the management of Waldenström macroglobulinaemia</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Biological and medical sciences</subject><subject>Cladribine - therapeutic use</subject><subject>diagnosis</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunopathology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Plasma Exchange</subject><subject>Prognosis</subject><subject>Rituximab</subject><subject>Stem Cell Transplantation - methods</subject><subject>Thalidomide - therapeutic use</subject><subject>treatment</subject><subject>Vidarabine - analogs & derivatives</subject><subject>Vidarabine - therapeutic use</subject><subject>Waldenstrom Macroglobulinemia - drug therapy</subject><subject>Waldenstrom Macroglobulinemia - immunology</subject><subject>Waldenstrom Macroglobulinemia - therapy</subject><subject>Waldenström macroglobulinaemia</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EoqXwCygb2CXM5GHHC4SgghZUiQ2IpeUkk5IqjxInov0xfoAfI6ER3eKNLc25nqvDmIXgYHeuVg56PLBd9NFxAQIHAumHzuaAjf8Gh2wMAMJG8MMROzFmBYAeBHjMRsj9UCCXY3Yza7OE8qwkY1Wl1byTVehSL6mgsrGq1HrTeUKlaervr6IbxXW1zKuo7RKaikyfsqNU54bOhnvCXh_uX6Zze_E8e5zeLuzYkyK0hQgoCiS6gJpHGoUbRTF1zVAmyMlLRMiJ-y5wyWXipkHCIY5JyhCEx7nvTdjl7t91XX20ZBpVZCamPNclVa1RXHCBrhAdGO7ArqkxNaVqXWeFrrcKQfXy1Er1jlTvSPXy1K88temi58OONioo2QcHWx1wMQDaxDpPa13GmdlzIvBC4H2H6x33meW0_XcBdfc071_eD6vLieo</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Johnson, S. A.</creator><creator>Birchall, J.</creator><creator>Luckie, C.</creator><creator>Oscier, D. G.</creator><creator>Owen, R. G.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200603</creationdate><title>Guidelines on the management of Waldenström macroglobulinaemia</title><author>Johnson, S. A. ; Birchall, J. ; Luckie, C. ; Oscier, D. G. ; Owen, R. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3978-775eb591201a6ba172bbce04819d16e3d786e64206969d2f5d60cce9980736643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Biological and medical sciences</topic><topic>Cladribine - therapeutic use</topic><topic>diagnosis</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunopathology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Plasma Exchange</topic><topic>Prognosis</topic><topic>Rituximab</topic><topic>Stem Cell Transplantation - methods</topic><topic>Thalidomide - therapeutic use</topic><topic>treatment</topic><topic>Vidarabine - analogs & derivatives</topic><topic>Vidarabine - therapeutic use</topic><topic>Waldenstrom Macroglobulinemia - drug therapy</topic><topic>Waldenstrom Macroglobulinemia - immunology</topic><topic>Waldenstrom Macroglobulinemia - therapy</topic><topic>Waldenström macroglobulinaemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, S. A.</creatorcontrib><creatorcontrib>Birchall, J.</creatorcontrib><creatorcontrib>Luckie, C.</creatorcontrib><creatorcontrib>Oscier, D. G.</creatorcontrib><creatorcontrib>Owen, R. G.</creatorcontrib><creatorcontrib>Haemato-Oncology Task Force of the British Committee for Standards in Haematology</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, S. A.</au><au>Birchall, J.</au><au>Luckie, C.</au><au>Oscier, D. G.</au><au>Owen, R. G.</au><aucorp>Haemato-Oncology Task Force of the British Committee for Standards in Haematology</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guidelines on the management of Waldenström macroglobulinaemia</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2006-03</date><risdate>2006</risdate><volume>132</volume><issue>6</issue><spage>683</spage><epage>697</epage><pages>683-697</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16487169</pmid><doi>10.1111/j.1365-2141.2005.05948.x</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2006-03, Vol.132 (6), p.683-697 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67671277 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Biological and medical sciences Cladribine - therapeutic use diagnosis Drug Therapy, Combination Enzyme Inhibitors - therapeutic use Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunologic Factors - therapeutic use Immunopathology Immunosuppressive Agents - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Plasma Exchange Prognosis Rituximab Stem Cell Transplantation - methods Thalidomide - therapeutic use treatment Vidarabine - analogs & derivatives Vidarabine - therapeutic use Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - immunology Waldenstrom Macroglobulinemia - therapy Waldenström macroglobulinaemia |
| title | Guidelines on the management of Waldenström macroglobulinaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A32%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guidelines%20on%20the%20management%20of%20Waldenstr%C3%B6m%20macroglobulinaemia&rft.jtitle=British%20journal%20of%20haematology&rft.au=Johnson,%20S.%20A.&rft.aucorp=Haemato-Oncology%20Task%20Force%20of%20the%20British%20Committee%20for%20Standards%20in%20Haematology&rft.date=2006-03&rft.volume=132&rft.issue=6&rft.spage=683&rft.epage=697&rft.pages=683-697&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2005.05948.x&rft_dat=%3Cproquest_cross%3E67671277%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67671277&rft_id=info:pmid/16487169&rfr_iscdi=true |